SCHEMBL7073753

SCHEMBL7073753

O=C(O)C[C@@H](CS(=O)(=O)c1ccc(O)cc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 1/20 0.50
GABBR1 Q9UBS5 1/20 0.50
HSD11B1 P28845 1/20 0.46
KDM4E B2RXH2 1/20 0.43
RECQL P46063 1/20 0.43
MAPT P10636 1/20 0.42
MMP2 P08253 1/20 0.41
MMP7 P09237 1/20 0.41
MMP14 P50281 1/20 0.41
CA2 P00918 1/20 0.40
CASP3 P42574 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
EEF2K O00418 3/20 0.39
CYP2C19 P33261 1/20 0.39
ESR1 P03372 2/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8909238 0.91 GABBR2 (0.56) GABBR2GABBR1HSD11B1KDM4ERECQL
SCHEMBL7077840 0.87 GABBR2 (0.49) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL7077860 0.87 GABBR2 (0.49) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL7073376 0.85 ALDH1A1 (0.46) HSD11B1MMP2ALDH1A1KMT2A
SCHEMBL7080823 0.83 GABBR2 (0.49) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL7073896 0.83 GABBR2 (0.39) GABBR2GABBR1CA2MEN1KMT2A
SCHEMBL5278801 0.81 BDKRB1 (0.47) GABBR2GABBR1KDM4EMAPTALDH1A1
SCHEMBL7133113 0.81 MEN1 (0.47) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL27603418 0.81 HSD11B1 (0.51) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL7079926 0.76 MAOA (0.48) GABBR2GABBR1MMP2CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed